BioCentury
ARTICLE | Company News

Vivalis, Sanofi deal

January 23, 2012 8:00 AM UTC

Vivalis and Sanofi Pasteur, the vaccines division of Sanofi, added an additional undisclosed infectious disease target to a June 2010 deal under which the division gained exclusive access to Vivalis' VIVA|Screen technology to discover human mAbs to treat and prevent nosocomial infections and other infectious diseases that are not preventable with vaccines. Sanofi will have exclusive, worldwide development and commercialization rights for any discovered antibodies, and will be responsible for all of Vivalis' research costs. Vivalis is eligible to receive up to €35 million ($44.4 million) in milestones for each target, plus royalties. Details were not disclosed (see BioCentury, June 14, 2010). ...